북미의 수의과 의료 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the North America veterinary healthcare market size is projected to expand from USD 27.42 billion in 2025 and USD 29.20 billion in 2026 to USD 39.99 billion by 2031, registering a CAGR of 6.41% between 2026 to 2031.

This report is Segmented by Product (Therapeutics [Vaccines, Parasiticides, and More] and Diagnostics [Immunodiagnostic Tests, and More]), Animal Type (Dogs & Cats, and More), Route of Administration (Oral, and More), End User (Veterinary Hospitals & Clinics, and More), and Geography (United States, Canada, and Mexico). The Market Forecasts are Provided in Terms of Value (USD).

North America Veterinary Healthcare Market Trends and Insights

Growth in Companion Animal Ownership

Pet-owning households continue to climb, reaching 70 million in the United States in 2024 and 7.9 million in Canada, with Mexico showing 70% household penetration. Younger owners increasingly adopt multiple pets at once, compressing routine-care cycles and straining under-staffed clinics. This intensifies demand for efficiency-enhancing POC diagnostics that deliver results during the same visit. Scheduling backlogs, particularly for wellness appointments, are steering corporate groups to extend weekend hours and to offer teletriage options that direct non-urgent cases to virtual platforms.

Increasing Pet Healthcare Expenditure

U.S. veterinary-care outlays grew from USD 39.8 billion in 2024 to USD 41.4 billion in 2025, while Canada allocated CAD 2.1 billion to veterinary services in 2023. Corporate groups segment offerings into tiered wellness packages versus high-acuity specialties, capturing both price-sensitive and premium spend without cannibalization. Although pet insurance premiums reached USD 4.7 billion in 2024, 94% of veterinarians still cite cost as a barrier to recommended care, signaling that coverage skews toward affluent clients.

Shortage of Veterinary Professionals

The AVMA projects a 15,000-veterinarian deficit by 2030, while Canada anticipates a 1,500-practitioner shortfall. Debt-to-income imbalance discourages graduates from rural practice ownership, concentrating talent in urban centers and raising wait times for elective care. Corporate consolidators are bidding up salaries with sign-on bonuses and loan-repayment packages, but the measures mostly re-shuffle existing clinicians rather than expand total supply. Burnout, driven by moral distress and long hours, further erodes retention.

Other drivers and restraints analyzed in the detailed report include:

1. Advancements in Veterinary Diagnostics and Therapeutics
2. Rising Adoption of Pet Insurance
3. High Cost of Advanced Veterinary Care

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Diagnostics revenue is poised to climb at a 6.43% CAGR, eclipsing therapeutic growth as practices embrace in-clinic molecular platforms that accelerate decision-making and generate consumable pull-through. SNAP immunoassays for heartworm and tick-borne panels are now featured in 80% of U.S. wellness visits, anchoring recurring kit sales that bolster the North American veterinary healthcare market for diagnostic consumables. Therapeutics continue to dominate absolute value; however, antimicrobial resistance constraints and heightened regulatory oversight temper volume expansion. Combination parasiticides, such as Simparica Trio and Credelio Quattro, demonstrate that convenience drives owner adherence, mitigating revenue leakage from missed doses. Within vaccines, livestock operators favor multivalent formulations that reduce handling stress, while companion-animal updates now incorporate chimeric technologies for broader strain coverage.

Companion animals retain 45.78% revenue in 2025, reflecting entrenched pet-humanization behaviors that propel specialty referrals and chronic-disease management. Nevertheless, poultry health spending will outpace all other categories, expanding at 6.66% CAGR on the back of post-HPAI biosecurity upgrades and stricter export certification rules. Diagnostic laboratories report a surge in avian PCR panels, while vaccine suppliers ramp production to meet flock-wide prophylaxis mandates. Ruminant uptake remains constrained by commodity-price volatility; however, screwworm-related trade disruptions are spurring cattle operators to integrate parasiticides and serology screens to regain U.S. market access.

Complete Report Scope:

• By Product
  • Therapeutics
    • Vaccines
    • Parasiticides
    • Anti-Infectives
    • Medical Feed Additives
    • Other Therapeutics
  • Diagnostics
    • Immunodiagnostic Tests
    • Molecular Diagnostics
    • Diagnostic Imaging
    • Clinical Chemistry
    • Other Diagnostics
• By Animal Type
  • Dogs & Cats
  • Horses
  • Ruminants
  • Swine
  • Poultry
  • Other Animal Types
• By Route Of Administration
  • Oral
  • Parenteral
  • Topical
  • Other Routes
• By End User
  • Veterinary Hospitals & Clinics
  • Reference Laboratories
  • Point-Of-Care / In-House Settings
  • Academic & Research Institutes
• By Country
  • United States
  • Canada
  • Mexico

List of Companies Covered in this Report:

1. Antech Diagnostics
2. Boehringer Ingelheim
3. Ceva Sante Animale
4. Covetrus
5. Dechra Pharmaceuticals
6. Elanco Animal Health Inc.
7. Henry Schein Animal Health
8. Heska
9. IDEXX
10. Mars Veterinary Health / VCA
11. Merck Animal Health (Merck & Co.)
12. Neogen
13. Patterson Companies (Animal Health)
14. Phibro Animal Health
15. Thermo Fisher Scientific (Vet)
16. Vetoquinol
17. Virbac Corp.
18. Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope Of The Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growth in Companion Animal Ownership
  • 4.2.2 Increasing Pet Healthcare Expenditure
  • 4.2.3 Advancements in Veterinary Diagnostics and Therapeutics
  • 4.2.4 Rising Adoption of Pet Insurance
  • 4.2.5 Expansion of Corporate Veterinary Chains
  • 4.2.6 Supportive Government Animal Health Policies
• 4.3 Market Restraints
  • 4.3.1 Shortage of Veterinary Professionals
  • 4.3.2 High Cost of Advanced Veterinary Care
  • 4.3.3 Stringent Regulatory Compliance Requirements
  • 4.3.4 Concerns Over Antimicrobial Resistance
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power Of Buyers
  • 4.7.2 Bargaining Power Of Suppliers
  • 4.7.3 Threat Of New Entrants
  • 4.7.4 Threat Of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Therapeutics
    • 5.1.1.1 Vaccines
    • 5.1.1.2 Parasiticides
    • 5.1.1.3 Anti-Infectives
    • 5.1.1.4 Medical Feed Additives
    • 5.1.1.5 Other Therapeutics
  • 5.1.2 Diagnostics
    • 5.1.2.1 Immunodiagnostic Tests
    • 5.1.2.2 Molecular Diagnostics
    • 5.1.2.3 Diagnostic Imaging
    • 5.1.2.4 Clinical Chemistry
    • 5.1.2.5 Other Diagnostics
• 5.2 By Animal Type
  • 5.2.1 Dogs & Cats
  • 5.2.2 Horses
  • 5.2.3 Ruminants
  • 5.2.4 Swine
  • 5.2.5 Poultry
  • 5.2.6 Other Animal Types
• 5.3 By Route Of Administration
  • 5.3.1 Oral
  • 5.3.2 Parenteral
  • 5.3.3 Topical
  • 5.3.4 Other Routes
• 5.4 By End User
  • 5.4.1 Veterinary Hospitals & Clinics
  • 5.4.2 Reference Laboratories
  • 5.4.3 Point-Of-Care / In-House Settings
  • 5.4.4 Academic & Research Institutes
• 5.5 By Country
  • 5.5.1 United States
  • 5.5.2 Canada
  • 5.5.3 Mexico

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (Includes Global-Level Overview, Market-Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)
  • 6.3.1 Antech Diagnostics
  • 6.3.2 Boehringer Ingelheim Animal Health
  • 6.3.3 Ceva Sante Animale
  • 6.3.4 Covetrus Inc.
  • 6.3.5 Dechra Pharmaceuticals PLC
  • 6.3.6 Elanco Animal Health Inc.
  • 6.3.7 Henry Schein Animal Health
  • 6.3.8 Heska Corporation
  • 6.3.9 IDEXX Laboratories Inc.
  • 6.3.10 Mars Veterinary Health / VCA
  • 6.3.11 Merck Animal Health (Merck & Co.)
  • 6.3.12 Neogen Corporation
  • 6.3.13 Patterson Companies (Animal Health)
  • 6.3.14 Phibro Animal Health Corporation
  • 6.3.15 Thermo Fisher Scientific (Vet)
  • 6.3.16 Vetoquinol SA
  • 6.3.17 Virbac Corp.
  • 6.3.18 Zoetis Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment